News Releases

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

Aug 20, 2026

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

Aug 10, 2026

Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026

Aug 03, 2026

Fractyl Health to Participate in Upcoming Investor Events

Jul 22, 2026

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Jul 15, 2026

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Jun 04, 2026

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

Jun 01, 2026

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

May 12, 2026

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

May 11, 2026

Investor Relations Contacts

Brian Luque, Head of Investor Relations and Corporate Development

Email: ir@fractyl.com
Phone: 951.206.1200